Glypican
C-terminally truncated human glypican-1. PDB 4acr
Identifiers
SymbolGlypican
PfamPF01153
InterProIPR001863
PROSITEPDOC00927
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary

Glypicans constitute one of the two major families of heparan sulfate proteoglycans, with the other major family being syndecans. Six glypicans have been identified in mammals, and are referred to as GPC1 through GPC6.[1][2] In Drosophila two glypicans have been identified, and these are referred to as dally (division abnormally delayed) and dally-like. One glypican has been identified in C. elegans.[3] Glypicans seem to play a vital role in developmental morphogenesis, and have been suggested as regulators for the Wnt [4][5][6]and Hedgehog cell signaling pathways. They have additionally been suggested as regulators for fibroblast growth factor and bone morphogenic protein signaling.[2]

Structure

While six glypicans have been identified in mammals, several characteristics remain consistent between these different proteins. First, the core protein of all glypicans is similar in size, approximately ranging between 60 and 70 kDa.[7] Additionally, in terms of amino acid sequence, the location of fourteen cysteine residues is conserved; however, researchers describe glypicans as having moderate similarity in amino acid sequence overall.[3] Nevertheless, it is thought that the fourteen conserved cysteine residues play a vital role in determining three-dimensional shape, thus suggesting the existence of a highly similar three-dimensional structure.[7] Overall, GPC3 and GPC5 have very similar primary structures with 43% sequence similarity. On the other hand, GPC1, GPC2, GPC4, and GPC6 have between 35% and 63% sequence similarity. Thus, GPC3 and GPC5 are often referred to as one subfamily of glypicans, with GPC1, GPC2, GPC4, and GPC6 constituting the other group.[3] Between the subfamilies of glypicans, there is about 25% sequence similarity.[2] Furthermore, the amino acid sequence and structure of each glypican is well-conserved between species; all vertebrate glypicans are more than 90% similar regardless of the species.[3]

For all members of the glypican family, the C-terminus of the protein is attached to the cell membrane covalently via a glycosylphosphatidylinositol (GPI) anchor. To allow for the addition of the GPI anchor, glypicans have a hydrophobic domain at the C-terminus of the protein. Within 50 amino acids of this GPI anchor, the heparan sulfate chains attach to the protein core. Therefore, unlike syndecans the heparan sulfate glycosaminoglycan chains attached to glypicans are located rather close to the cell-membrane.[7] The glypicans found in vertebrates, Drosophila, and C. elegans all have an N-terminal signal sequence.[3]

Function

Glypicans are critically involved in developmental morphogenesis, and have been implicated as regulators in several cell signaling pathways.[3] These include the Wnt and Hedgehog signaling pathways, as well as signaling of fibroblast growth factors and bone morphogenic proteins. The regulating processes performed by glypicans can either stimulate or inhibit specific cellular processes.[2] The mechanisms by which glypicans regulate cellular pathways are not entirely clear. One commonly proposed mechanism suggests that glypicans behave as co-receptors which bind both the ligand and the receptor. Wnt recognizes a heparan sulfate structure on GPC3, which contains IdoA2S and GlcNS6S, and that the 3-O-sulfation in GlcNS6S3S enhances the binding of Wnt to the heparan sulfate glypican.[5] A cysteine-rich domain at the N-lobe of GPC3 has been identified to form a Wnt-binding hydrophobic groove including phenylalanine-41 that interacts with Wnt.[6] Glypicans are expressed in various different amounts depending on the tissue, and they also are expressed to different degrees during the different stages of development.[8] Drosophila Dally mutants have irregular wing, antenna, genitalia, and brain development.[2]

Location

GPC5 and GPC6 are next to one another on chromosome 13q32 (in humans). GPC3 and GPC4 are also found next to one another, and are located on the human chromosome Xq26.[3] Some suggest that this implies that these glypicans arose because of a gene duplication event.[8] The gene for GPC1 is found on chromosome 2q36. Nearby genes include ZIC2, ZIC3, COL4A1/2, and COL4A3/4.[3]

Simpson-Golabi-Behmel Syndrome

Since 1996, it has been known that patients with Simpson–Golabi–Behmel syndrome (SGBS) have mutations in GPC3. Because this is an X-linked syndrome, it appears to affect males more significantly than females. While the phenotype associated with this condition can vary from mild to lethal, common symptoms include macroglossia, cleft palate, syndactyly, polydactyly, cystic and dysplastic kidneys, congenital heart defects, and a distinct facial appearance. Additional symptoms/characteristics have also been noted. Overall, these symptoms/characteristics are distinguished by prenatal and post-natal overgrowth. Typically, patients identified with SGBS have point mutations or microdeletions in the gene encoding GPC3, and the mutations can occur in multiple different locations of the gene. No correlation has been noticed between the location of the GPC3 mutation and the phenotypic manifestation of this disease. therefore, it is inferred that SGBS results due to a nonfunctional GPC3 protein. Researchers currently speculate that GPC3 is a negative regulator of cell proliferation, and this would explain why patients with SGBS experience overgrowth.[2]

Implications in cancer

Abnormal expression of glypicans has been noted in multiple types of cancer, including human hepatocellular carcinoma, ovarian cancer, mesothelioma, pancreatic cancer, glioma, breast cancer and recently GPC2 in neuroblastoma.[9] Most research involving the relationship between glypicans and cancer has focused on GPC1[10][11] and GPC3.[1]

A correlation between GPC3 expression levels and various types of cancer.[1] To summarize these findings, it can be generally said that tissues which normally express GPC3 exhibit down-regulation of GPC3 expression during tumor progression. Similarly, the corresponding cancers of tissues which normally do not exhibit GPC3 expression often express GPC3. Furthermore, oftentimes GPC3 expression occurs during embryonic development in these tissues, and is subsequently re-expressed during tumor progression.[8] GPC3 expression can be detected in normal ovarian cells; however, several ovarian cancer cell lines do not express GPC3.[12][13] On the other hand, GPC3 expression is undetectable in healthy adult liver cells, while GPC3 expression occurs in the majority of human hepatocellular carcinomas.[1] A similar correlation has been found in colorectal tumors. GPC3 is an oncofetal protein in both liver and intestine, as GPC3 is typically only expressed during embryonic development but also found in cancerous tumors.[8]

GPC3 mutations do not occur in the coding sequence of this protein. Ovarian cancer cell lines do not express GPC3 due to hypermethylation of the GPC3 promoter. After removing these methyl groups, the authors restored expression of GPC3.[12] Mesothelioma cell lines contain a GPC3 promoter which is incorrectly methylated.[13] Re-establishing expression of GPC3 prevented colony-forming by cancerous cells.[12][13]

GPC1 implications in cancer

In addition to GPC3, GPC1 has also been implicated in tumor progression, especially in pancreatic cancer, glioma, and breast cancer.[2] GPC1 expression is severely high in pancreatic ductal adenocarcinoma cells, and results indicate that GPC1 expression is linked to cancer progression, including tumor growth, angiogenesis and metastasis. In addition to overexpression of GPC1 on the plasma membrane of pancreatic ductal adenocarcinoma cells. GPC1 is released into the tumor microenvironment by these cells. Because glypicans play a role in growth factor binding, researchers have speculated that increased levels of GPC1 in the tumor microenvironment may function to store growth factors for cancerous cells.[2] By reducing the level of GCP1 in pancreatic adenocarcinoma cells, the growth of these cells was hindered. By reducing the levels of expressed GCP1 immunocompromised mice, slowed the growth tumors and reduced angiogenesis and metastases when compared with control GCP1 mice. GPC1 is highly expressed in human glioma blood vessel endothelial cells. Furthermore, increasing the level of GPC1 in mouse brain endothelial cells results in cell growth and stimulates mitosis in response to the angiogenic factor, FGF2. This suggests that GPC1 acts as a regulator for cell cycle progression.[14] GPC1 expression is well-above normal in human breast cancers, while expression of GPC1 is low in healthy breast tissue. Furthermore, expression was not significantly increased for any other glypican. GPC1 plays a role in heparin-binding and cell cycle progression in the breast tissue.[15]

GPC2 implications in cancer

Glypican-2 (GPC2) is a cell surface heparan sulfate proteoglycan that is important for neuronal cell adhesion and neurite outgrowth. GPC2 protein is highly expressed in about half of neuroblastoma cases and that high GPC2 expression correlates with poor overall survival compared with patients with low GPC2 expression, suggesting GPC2 as a therapeutic target in neuroblastoma.[9][16] Silencing of GPC2 by CRISPR/Cas9 results in the inhibition of neuroblastoma tumor cell growth. GPC2 silencing inactivates Wnt/β-catenin signaling and reduces the expression of the target gene N-Myc, an oncogenic driver of neuroblastoma tumorigenesis.[9] Immunotoxins and chimeric antigen receptor (CAR) T cells targeting GPC2 have been developed for treating neuroblastoma and other GPC2-positive cancers. Immunotoxin treatment inhibits neuroblastoma growth in mice. CAR T cells targeting GPC2 can eliminate tumors in a metastatic neuroblastoma mouse model.[9] A GPC2-directed antibody-drug conjugate (ADC) is capable of killing GPC2-expressing neuroblastoma cells.[16]

Molecular biology

Glypicans can modify cell signaling pathways and contribute to cellular proliferation and tissue growth. In Drosophila, the glypican dally assists diffusion of the BMP-family growth-promoting morphogen Decapentaplegic in the developing wing, while the developing haltere lacks dally and remains small.[17] Extracellular localization of the other glypican in Drosophila, dally-like, is also required for the proper level of Hedgehog signaling in the developing wing.[18]

Clinical

In humans, glypican-1 is overexpressed in breast[15] and brain cancers (gliomas),[19] while glypican-3 is overexpressed in liver cancers.[20][1] Glypican-2 is overexpressed in neuroblastoma.[9]

Mutations in this gene have also been associated with biliary atresia.[21]

References

  1. 1 2 3 4 5 Ho M, Kim H (February 2011). "Glypican-3: a new target for cancer immunotherapy". European Journal of Cancer. 47 (3): 333–8. doi:10.1016/j.ejca.2010.10.024. PMC 3031711. PMID 21112773.
  2. 1 2 3 4 5 6 7 8 Filmus J, Capurro M, Rast J (2008). "Glypicans". Genome Biology. 9 (5): 224. doi:10.1186/gb-2008-9-5-224. PMC 2441458. PMID 18505598.
  3. 1 2 3 4 5 6 7 8 De Cat B, David G (April 2001). "Developmental roles of the glypicans". Seminars in Cell & Developmental Biology. 12 (2): 117–25. doi:10.1006/scdb.2000.0240. PMID 11292377.
  4. ↑ Gao, Wei; Ho, Mitchell (2011). "The role of glypican-3 in regulating Wnt in hepatocellular carcinomas". Cancer Reports. 1 (1): 14–19. PMC 3343874. PMID 22563565.
  5. 1 2 Gao, Wei; Xu, Yongmei; Liu, Jian; Ho, Mitchell (May 17, 2016). "Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate". Scientific Reports. 6: 26245. Bibcode:2016NatSR...626245G. doi:10.1038/srep26245. ISSN 2045-2322. PMC 4869111. PMID 27185050.
  6. 1 2 Li, Na; Wei, Liwen; Liu, Xiaoyu; Bai, Hongjun; Ye, Yvonne; Li, Dan; Li, Nan; Baxa, Ulrich; Wang, Qun; Lv, Ling; Chen, Yun (October 2019). "A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice". Hepatology. 70 (4): 1231–1245. doi:10.1002/hep.30646. ISSN 1527-3350. PMC 6783318. PMID 30963603.
  7. 1 2 3 Filmus J, Selleck SB (August 2001). "Glypicans: proteoglycans with a surprise" (PDF). The Journal of Clinical Investigation. 108 (4): 497–501. doi:10.1172/JCI13712. PMC 209407. PMID 11518720.
  8. 1 2 3 4 Filmus J (March 2001). "Glypicans in growth control and cancer". Glycobiology. 11 (3): 19R–23R. doi:10.1093/glycob/11.3.19r. PMID 11320054.
  9. 1 2 3 4 5 Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. PMC 5559039. PMID 28739923.
  10. ↑ Pan, Jiajia; Ho, Mitchell (2021-11-01). "Role of glypican-1 in regulating multiple cellular signaling pathways". American Journal of Physiology. Cell Physiology. 321 (5): C846–C858. doi:10.1152/ajpcell.00290.2021. ISSN 1522-1563. PMC 8616591. PMID 34550795.
  11. ↑ Pan, Jiajia; Li, Nan; Renn, Alex; Zhu, Hu; Chen, Lu; Shen, Min; Hall, Matthew D.; Qian, Min; Pastan, Ira; Ho, Mitchell (2022-06-01). "GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling". Molecular Cancer Therapeutics. 21 (6): 960–973. doi:10.1158/1535-7163.MCT-21-0778. ISSN 1538-8514. PMC 9167738. PMID 35312769.
  12. 1 2 3 Lin H, Huber R, Schlessinger D, Morin PJ (February 1999). "Frequent silencing of the GPC3 gene in ovarian cancer cell lines". Cancer Research. 59 (4): 807–10. PMID 10029067.
  13. 1 2 3 Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR (January 2000). "Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma". Oncogene. 19 (3): 410–6. doi:10.1038/sj.onc.1203322. PMID 10656689.
  14. ↑ Qiao D, Yang X, Meyer K, Friedl A (July 2008). "Glypican-1 regulates anaphase promoting complex/cyclosome substrates and cell cycle progression in endothelial cells". Molecular Biology of the Cell. 19 (7): 2789–801. doi:10.1091/mbc.E07-10-1025. PMC 2441674. PMID 18417614.
  15. 1 2 Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M (July 2001). "Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells". Cancer Research. 61 (14): 5562–9. PMID 11454708.
  16. 1 2 Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM (September 2017). "Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma". Cancer Cell. 32 (3): 295–309.e12. doi:10.1016/j.ccell.2017.08.003. PMC 5600520. PMID 28898695.
  17. ↑ Crickmore MA, Mann RS (January 2007). "Hox control of morphogen mobility and organ development through regulation of glypican expression". Development. 134 (2): 327–34. doi:10.1242/dev.02737. PMID 17166918.
  18. ↑ Gallet A, Staccini-Lavenant L, Thérond PP (May 2008). "Cellular trafficking of the glypican Dally-like is required for full-strength Hedgehog signaling and wingless transcytosis". Developmental Cell. 14 (5): 712–25. doi:10.1016/j.devcel.2008.03.001. PMID 18477454.
  19. ↑ Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A (June 2006). "Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells". The American Journal of Pathology. 168 (6): 2014–26. doi:10.2353/ajpath.2006.050800. PMC 1606624. PMID 16723715.
  20. ↑ Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT (April 2008). "Biology of hepatocellular carcinoma". Annals of Surgical Oncology. 15 (4): 962–71. doi:10.1245/s10434-007-9730-z. PMID 18236113. S2CID 20684585.
  21. ↑ Cui S, Leyva-Vega M, Tsai EA, EauClaire SF, Glessner JT, Hakonarson H, Devoto M, Haber BA, Spinner NB, Matthews RP (May 2013). "Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene". Gastroenterology. 144 (5): 1107–1115.e3. doi:10.1053/j.gastro.2013.01.022. PMC 3736559. PMID 23336978.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.